Sublingual administration sits at 6085%
When BPC-157 is well matched to the patient and the injury, expected benefits may include reduced localized discomfort, improved range of motion, better tolerance of rehabilitation exercises, improved soft-tissue recovery, and faster return to normal training or activity
By avoiding the growth hormone receptor/IGF-1 pathway entirely, AOD-9604 eliminates the appetite-modulating effects that make growth hormone therapy challenging for weight management
Designed for consistent daily use with a clean formulation suitable for a wide range of lifestyles.
Rodent Achilles transection and medial collateral ligament transection studies, with healing scored by tensiometry, histology, and functional gait analysis